Thomas Eskew, MD
Vascular Surgery · Wilmington, NCNPI 1700866019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,676 and has fallen 62.1% since, to $635 in 2025.
Across 196 payments — averaging $33.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$1K
- Inari Medical, Inc.$532
- Johnson & Johnson$497
- W. L. Gore & Associates, Inc.$421
- Imbed Biosciences Inc.$345
- plus $2K from 34 others
What the payments were for
- Food & beverage$6,616100%
- Entertainment$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $1,537 |
| Boston Scientific | 44 | $1,163 |
| Inari Medical, Inc. | 5 | $532 |
| Johnson & Johnson(2 entities) | 22 | $497 |
| W. L. Gore & Associates, Inc. | 7 | $421 |
| Imbed Biosciences Inc. | 11 | $345 |
| Bard Peripheral Vascular, Inc. | 9 | $225 |
| Silk Road Medical, Inc. | 3 | $199 |
| Vasorum USA Inc. | 1 | $194 |
| Smith+Nephew | 9 | $150 |
| Epsfl, LLC | 1 | $140 |
| Stryker | 2 | $129 |
| Pfizer | 6 | $103 |
| Fujifilm Healthcare Americas Corporation | 1 | $98 |
| Abbott | 5 | $87 |
| Organogenesis Inc. | 3 | $73 |
| Cardiovascular Systems Inc. | 3 | $71 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $68 |
| Shockwave Medical, Inc | 3 | $62 |
| BD | 2 | $50 |
| Artivion, Inc. | 3 | $49 |
| Paratek Pharmaceuticals, Inc. | 3 | $48 |
| Lemaitre Vascular, Inc. | 2 | $47 |
| Acell, Inc. | 2 | $35 |
| Davol Inc. | 2 | $33 |
| Melinta Therapeutics, LLC | 2 | $29 |
| Terumo Medical Corporation | 1 | $26 |
| Sanara Medtech Inc. | 2 | $25 |
| Abiomed | 1 | $24 |
| Neuros Medical, Inc. | 1 | $21 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $18 |
| Cashflow Solutions, LLC | 1 | $17 |
| Merit Medical Systems Inc | 1 | $17 |
| Solventum Corporation | 1 | $17 |
| Angiodynamics, Inc. | 1 | $16 |
| Penumbra, Inc. | 1 | $15 |
| LSI Solutions Inc | 1 | $14 |
| Next Science LLC | 1 | $14 |
| Triad Life Sciences Inc. | 1 | $13 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$601
- CT THROMBECTOMY SYSTEM KIT$316
- GENERAL VASCULAR INTERVENTION$245
- CELT ACD$194
- ENROUTE Transcarotid Neuroprotection System$161
- ENROUTE Transcarotid Stent System$161
- ENHANCE Transcarotid Peripheral Access Kit$161
- ENROUTE 0.014 Guidewire$161
- ENDURANT IIS$151
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$144
- GORE TAG Thoracic Branch Endoprosthesis$140
- Heli-FX EndoAnchor System$139
- Endurant$125
How this compares
$6,634 in reported general payments places this provider in the 65th percentile of 119 vascular surgery providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $24,160 |
| XareltoRivaroxaban | 27 | $23,858 |
| BrilintaTicagrelor | 11 | $5,621 |
| ClopidogrelClopidogrel Bisulfate | 204 | $1,813 |
| Cilostazol | 61 | $1,419 |
| Gabapentin | 16 | $128 |
| Tramadol Hcl | 15 | $99 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $77 |
| Furosemide | 19 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $103 | $24,16027 claims |
| Johnson & JohnsonXarelto | $497 | $23,85827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 119 vascular surgery providers in North Carolina.
Other vascular surgery in Wilmington
- Dale CoffeyWilmington$6K
- Frank ArkoCharlotte$2.6M
- Erin MurphyCharlotte$598K
- Robert MendesRaleigh$408K
- Ellen DillavouRaleigh$284K
- Mark FarberChapel Hill$245K
- Hector Crespo SotoCharlotte$178K
- Rebecca KelsoCharlotte$148K
- William MarstonChapel Hill$83K
- Bryan EhlertGoldsboro$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.